A nontuberculous mycobacterial (NTM) infection is an infectious disease caused by various species of mycobacteria other than Mycobacterium tuberculosis, which is responsible for tuberculosis (TB). NTM infections are primarily significant due to their impact on human health and their interaction with the immune system.
The primary classes of drugs used to treat nontuberculous mycobacterial infections include macrolides, rifampin, aminoglycosides, and others. Macrolides are a class of antibiotics commonly employed in the treatment of various bacterial infections. These drugs can be administered through different routes, including oral, parenteral (injectable), and others, and are distributed through various channels, such as hospital pharmacies, retail pharmacies, and online pharmacies.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.
The nontuberculous mycobacterial infection market research report is one of a series of new reports from The Business Research Company that provides nontuberculous mycobacterial infection market statistics, including nontuberculous mycobacterial infection industry global market size, regional shares, competitors with a nontuberculous mycobacterial infection market share, detailed nontuberculous mycobacterial infection market segments, market trends and opportunities and any further data you may need to thrive in the nontuberculous mycobacterial infection industry. This nontuberculous mycobacterial infection market research report delivers a complete perspective on everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The nontuberculous mycobacterial infection market size has grown steadily in recent years. It will grow from $14.25 billion in 2024 to $14.96 billion in 2025 at a compound annual growth rate (CAGR) of 5.0%. The growth in the historic period can be attributed to improved diagnostics, aging population, cystic fibrosis awareness, immunosuppressive medications.
The nontuberculous mycobacterial infection market size is expected to see strong growth in the next few years. It will grow to $19.37 billion in 2029 at a compound annual growth rate (CAGR) of 6.7%. The growth in the forecast period can be attributed to antimicrobial drug development, increasing ntm awareness, advances in genetic research, telehealth and remote monitoring. Major trends in the forecast period include personalized treatment, regulatory focus, combination therapies, digital health tools.
The forecast of 6.7% growth over the next five years remains unchanged from the previous projection for this market. This reduction is primarily due to the impact of tariffs between the US and other countries. The imposition of tariffs may pose a significant challenge for the U.S. by restricting access to clarithromycin-resistant strain diagnostics and inhaled amikacin solutions imported from Germany and India, potentially compromising infection control and increasing pulmonology treatment burdens. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.
The increasing prevalence of chronic obstructive pulmonary disease (COPD) is set to drive the growth of the nontuberculous mycobacterial infection market in the future. COPD, a chronic respiratory ailment characterized by persistent and often progressive lung airflow limitation, is closely linked to nontuberculous mycobacterial (NTM) infections, resulting in a more pronounced decline in forced expiratory volume in one second (FEV1) and an elevated exacerbation rate. The weakened immune system and lung tissue damage caused by COPD make it more susceptible to NTM bacterial lung infections. For example, as of March 2023, The Scottish Public Health Observatory (ScotPHO), a public health body in Scotland, reported a rise in COPD rates from 2021 to 2022, with male rates increasing from 83.2 to 97.6 per 100,000 individuals, and female rates rising from 72.6 to 97.3. Consequently, the burgeoning prevalence of chronic obstructive pulmonary disease (COPD) propels the nontuberculous mycobacterial infection market's growth.
The growing prevalence of infectious diseases is expected to drive the expansion of the nontuberculous mycobacterial (NTM) infection market in the coming years. Infectious diseases are illnesses caused by harmful microorganisms, such as bacteria, viruses, fungi, or parasites, that can be transmitted between individuals, leading to a range of symptoms and health complications. As the incidence of infectious diseases, including those that can lead to NTM infections, rises, the market for NTM infections may experience growth. This is due to increased awareness of these infections, leading to more frequent diagnostic testing, earlier detection, enhanced research and development for NTM treatments, and a higher demand for therapies targeting NTM pathogens as healthcare attention on infectious diseases intensifies. For example, in November 2024, the United Nations International Children's Emergency Fund (UNICEF), a US-based intergovernmental organization, reported that pneumonia was the leading infectious disease responsible for the deaths of over 700,000 children annually, equating to around 2,000 deaths per day. Therefore, the rising prevalence of infectious diseases is driving the growth of the NTM infection market.
Leading companies in the nontuberculous mycobacterial (NTM) infection market are adopting new treatment approval strategies, such as Fast Track designation for drug approvals, to maintain their market position. The Fast Track designation, granted by the FDA, is a process that accelerates the development and review of drugs intended for serious conditions with unmet medical needs. For example, in July 2022, the U.S.-based Food and Drug Administration (FDA) granted Fast Track Designation to NUZYRA for the treatment of NTM lung disease caused by Mycobacterium avium complex (MAC). NUZYRA (omadacycline) is an innovative broad-spectrum antibiotic developed to fight serious bacterial infections, including those caused by resistant strains. This designation helps speed up the development and review process for NUZYRA, addressing critical unmet medical needs.
In February 2023, Qurient Co. Ltd., a Korea-based biotech company, entered into a partnership with TB Alliance with the goal of developing telacebec, a drug for the treatment of tuberculosis and other nontuberculous mycobacterial (NTM) infections. The partnership grants TB Alliance the exclusive global license for Telacebec. This signifies that TB Alliance will have the authority to continue its work on the medicine and market it on an international scale. TB Alliance, a South Africa-based non-profit organization, is dedicated to developing and delivering cost-effective TB medications.
Major companies operating in the nontuberculous mycobacterial infection market are Pfizer Inc., Johnson & Johnson, F. Hoffman La Roche AG, Merck & Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A., Bristol Myers Squibb, AstraZeneca PLC, Abbott Laboratories, GlaxoSmithKline PLC, Takeda Pharmaceutical Company, Eli Lilly and Company, C.H. Boehringer Sohn AG & Co. KG, Teva Pharmaceutical Industries Ltd., Mylan N.V., Astellas Pharma Inc., Vertex Pharmaceuticals Inc., Sun Pharmaceutical Industries Ltd., Horizon Therapeutics PLC, Lupin Limited, BioMarin Pharmaceutical Inc., Ionis Pharmaceuticals Inc., Insmed Incorporated, Paratek Pharmaceuticals Inc., Spero Therapeutics Inc., Aradigm Corporation, Dauntless Pharmaceuticals Inc., Validus Pharmaceuticals LLC.
North America was the largest region in the nontuberculous mycobacterial infection market in 2024. North America is expected to be the fastest-growing region in the forecast period. The regions covered in nontuberculous mycobacterial infection report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the nontuberculous mycobacterial infection market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, and Spain.
The nontuberculous mycobacterial infection market consists of revenues earned by entities by providing services such as treatment planning, antibiotic therapy, monitoring and follow-up. The market value includes the value of related goods sold by the service provider or included within the service offering. The nontuberculous mycobacterial infection market also includes sales of azithromycin, rifampin, ethambutol, streptomycin, medical equipment, pulmonary rehabilitation and supportive care products. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Nontuberculous Mycobacterial Infection Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on nontuberculous mycobacterial infection market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for nontuberculous mycobacterial infection ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The nontuberculous mycobacterial infection market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
- Markets Covered:1) By Drug Class: Macrolides; Rifampin; Aminoglycoside; Other Drug Classes
- 2) By Route Of Administration: Oral; Parenteral; Other Routes
- 3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
- Subsegments:
- 1) By Macrolides: Azithromycin; Clarithromycin
- 2) By Rifampin: Rifampin; Rifabutin
- 3) By Aminoglycoside: Amikacin; Streptomycin
- 4) By Other Drug Classes: Ethambutol; Clofazimine; Linezolid
- Companies Mentioned: Pfizer Inc.; Johnson & Johnson; F. Hoffman La Roche AG; Merck & Co. Inc.; AbbVie Inc.; Bayer AG; Novartis AG; Sanofi S.A.; Bristol Myers Squibb; AstraZeneca plc; Abbott Laboratories; GlaxoSmithKline plc; Takeda Pharmaceutical Company; Eli Lilly and Company; C.H. Boehringer Sohn AG & Co. KG; Teva Pharmaceutical Industries Ltd.; Mylan N.V.; Astellas Pharma Inc.; Vertex Pharmaceuticals Inc.; Sun Pharmaceutical Industries Ltd.; Horizon Therapeutics Plc; Lupin Limited; BioMarin Pharmaceutical Inc.; Ionis Pharmaceuticals Inc.; Insmed Incorporated; Paratek Pharmaceuticals Inc.; Spero Therapeutics Inc.; Aradigm Corporation; Dauntless Pharmaceuticals Inc.; Validus Pharmaceuticals LLC
- Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
- Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
- Time Series: Five years historic and ten years forecast.
- Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
- Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
- Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
- Delivery Format: PDF, Word and Excel Data Dashboard.
Table of Contents
1. Executive Summary
2. Nontuberculous Mycobacterial Infection Market Characteristics
3. Nontuberculous Mycobacterial Infection Market Trends And Strategies
4. Nontuberculous Mycobacterial Infection Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market
- 4.1. Supply Chain Impact from Tariff War & Trade Protectionism
5. Global Nontuberculous Mycobacterial Infection Growth Analysis And Strategic Analysis Framework
- 5.1. Global Nontuberculous Mycobacterial Infection PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
- 5.2. Analysis Of End Use Industries
- 5.3. Global Nontuberculous Mycobacterial Infection Market Growth Rate Analysis
- 5.4. Global Nontuberculous Mycobacterial Infection Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
- 5.5. Global Nontuberculous Mycobacterial Infection Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
- 5.6. Global Nontuberculous Mycobacterial Infection Total Addressable Market (TAM)
6. Nontuberculous Mycobacterial Infection Market Segmentation
- 6.1. Global Nontuberculous Mycobacterial Infection Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Macrolides
- Rifampin
- Aminoglycoside
- Other Drug Classes
- 6.2. Global Nontuberculous Mycobacterial Infection Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Oral
- Parenteral
- Other Routes
- 6.3. Global Nontuberculous Mycobacterial Infection Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- 6.4. Global Nontuberculous Mycobacterial Infection Market, Sub-Segmentation Of Macrolides, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Azithromycin
- Clarithromycin
- 6.5. Global Nontuberculous Mycobacterial Infection Market, Sub-Segmentation Of Rifampin, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Rifampin
- Rifabutin
- 6.6. Global Nontuberculous Mycobacterial Infection Market, Sub-Segmentation Of Aminoglycoside, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Amikacin
- Streptomycin
- 6.7. Global Nontuberculous Mycobacterial Infection Market, Sub-Segmentation Of Other Drug Classes, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Ethambutol
- Clofazimine
- Linezolid
7. Nontuberculous Mycobacterial Infection Market Regional And Country Analysis
- 7.1. Global Nontuberculous Mycobacterial Infection Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 7.2. Global Nontuberculous Mycobacterial Infection Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8. Asia-Pacific Nontuberculous Mycobacterial Infection Market
- 8.1. Asia-Pacific Nontuberculous Mycobacterial Infection Market Overview
- Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
- 8.2. Asia-Pacific Nontuberculous Mycobacterial Infection Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 8.3. Asia-Pacific Nontuberculous Mycobacterial Infection Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 8.4. Asia-Pacific Nontuberculous Mycobacterial Infection Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
9. China Nontuberculous Mycobacterial Infection Market
- 9.1. China Nontuberculous Mycobacterial Infection Market Overview
- 9.2. China Nontuberculous Mycobacterial Infection Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
- 9.3. China Nontuberculous Mycobacterial Infection Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
- 9.4. China Nontuberculous Mycobacterial Infection Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
10. India Nontuberculous Mycobacterial Infection Market
- 10.1. India Nontuberculous Mycobacterial Infection Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 10.2. India Nontuberculous Mycobacterial Infection Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 10.3. India Nontuberculous Mycobacterial Infection Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11. Japan Nontuberculous Mycobacterial Infection Market
- 11.1. Japan Nontuberculous Mycobacterial Infection Market Overview
- 11.2. Japan Nontuberculous Mycobacterial Infection Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 11.3. Japan Nontuberculous Mycobacterial Infection Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 11.4. Japan Nontuberculous Mycobacterial Infection Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12. Australia Nontuberculous Mycobacterial Infection Market
- 12.1. Australia Nontuberculous Mycobacterial Infection Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 12.2. Australia Nontuberculous Mycobacterial Infection Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 12.3. Australia Nontuberculous Mycobacterial Infection Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13. Indonesia Nontuberculous Mycobacterial Infection Market
- 13.1. Indonesia Nontuberculous Mycobacterial Infection Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 13.2. Indonesia Nontuberculous Mycobacterial Infection Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 13.3. Indonesia Nontuberculous Mycobacterial Infection Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14. South Korea Nontuberculous Mycobacterial Infection Market
- 14.1. South Korea Nontuberculous Mycobacterial Infection Market Overview
- 14.2. South Korea Nontuberculous Mycobacterial Infection Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 14.3. South Korea Nontuberculous Mycobacterial Infection Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 14.4. South Korea Nontuberculous Mycobacterial Infection Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15. Western Europe Nontuberculous Mycobacterial Infection Market
- 15.1. Western Europe Nontuberculous Mycobacterial Infection Market Overview
- 15.2. Western Europe Nontuberculous Mycobacterial Infection Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 15.3. Western Europe Nontuberculous Mycobacterial Infection Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 15.4. Western Europe Nontuberculous Mycobacterial Infection Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16. UK Nontuberculous Mycobacterial Infection Market
- 16.1. UK Nontuberculous Mycobacterial Infection Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 16.2. UK Nontuberculous Mycobacterial Infection Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 16.3. UK Nontuberculous Mycobacterial Infection Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17. Germany Nontuberculous Mycobacterial Infection Market
- 17.1. Germany Nontuberculous Mycobacterial Infection Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 17.2. Germany Nontuberculous Mycobacterial Infection Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 17.3. Germany Nontuberculous Mycobacterial Infection Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18. France Nontuberculous Mycobacterial Infection Market
- 18.1. France Nontuberculous Mycobacterial Infection Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 18.2. France Nontuberculous Mycobacterial Infection Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 18.3. France Nontuberculous Mycobacterial Infection Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19. Italy Nontuberculous Mycobacterial Infection Market
- 19.1. Italy Nontuberculous Mycobacterial Infection Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 19.2. Italy Nontuberculous Mycobacterial Infection Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 19.3. Italy Nontuberculous Mycobacterial Infection Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20. Spain Nontuberculous Mycobacterial Infection Market
- 20.1. Spain Nontuberculous Mycobacterial Infection Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 20.2. Spain Nontuberculous Mycobacterial Infection Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 20.3. Spain Nontuberculous Mycobacterial Infection Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21. Eastern Europe Nontuberculous Mycobacterial Infection Market
- 21.1. Eastern Europe Nontuberculous Mycobacterial Infection Market Overview
- 21.2. Eastern Europe Nontuberculous Mycobacterial Infection Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 21.3. Eastern Europe Nontuberculous Mycobacterial Infection Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 21.4. Eastern Europe Nontuberculous Mycobacterial Infection Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22. Russia Nontuberculous Mycobacterial Infection Market
- 22.1. Russia Nontuberculous Mycobacterial Infection Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 22.2. Russia Nontuberculous Mycobacterial Infection Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 22.3. Russia Nontuberculous Mycobacterial Infection Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23. North America Nontuberculous Mycobacterial Infection Market
- 23.1. North America Nontuberculous Mycobacterial Infection Market Overview
- 23.2. North America Nontuberculous Mycobacterial Infection Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 23.3. North America Nontuberculous Mycobacterial Infection Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 23.4. North America Nontuberculous Mycobacterial Infection Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24. USA Nontuberculous Mycobacterial Infection Market
- 24.1. USA Nontuberculous Mycobacterial Infection Market Overview
- 24.2. USA Nontuberculous Mycobacterial Infection Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 24.3. USA Nontuberculous Mycobacterial Infection Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 24.4. USA Nontuberculous Mycobacterial Infection Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25. Canada Nontuberculous Mycobacterial Infection Market
- 25.1. Canada Nontuberculous Mycobacterial Infection Market Overview
- 25.2. Canada Nontuberculous Mycobacterial Infection Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 25.3. Canada Nontuberculous Mycobacterial Infection Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 25.4. Canada Nontuberculous Mycobacterial Infection Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26. South America Nontuberculous Mycobacterial Infection Market
- 26.1. South America Nontuberculous Mycobacterial Infection Market Overview
- 26.2. South America Nontuberculous Mycobacterial Infection Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 26.3. South America Nontuberculous Mycobacterial Infection Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 26.4. South America Nontuberculous Mycobacterial Infection Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27. Brazil Nontuberculous Mycobacterial Infection Market
- 27.1. Brazil Nontuberculous Mycobacterial Infection Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 27.2. Brazil Nontuberculous Mycobacterial Infection Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 27.3. Brazil Nontuberculous Mycobacterial Infection Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28. Middle East Nontuberculous Mycobacterial Infection Market
- 28.1. Middle East Nontuberculous Mycobacterial Infection Market Overview
- 28.2. Middle East Nontuberculous Mycobacterial Infection Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 28.3. Middle East Nontuberculous Mycobacterial Infection Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 28.4. Middle East Nontuberculous Mycobacterial Infection Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29. Africa Nontuberculous Mycobacterial Infection Market
- 29.1. Africa Nontuberculous Mycobacterial Infection Market Overview
- 29.2. Africa Nontuberculous Mycobacterial Infection Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 29.3. Africa Nontuberculous Mycobacterial Infection Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 29.4. Africa Nontuberculous Mycobacterial Infection Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
30. Nontuberculous Mycobacterial Infection Market Competitive Landscape And Company Profiles
- 30.1. Nontuberculous Mycobacterial Infection Market Competitive Landscape
- 30.2. Nontuberculous Mycobacterial Infection Market Company Profiles
- 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. F. Hoffman La Roche AG Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
31. Nontuberculous Mycobacterial Infection Market Other Major And Innovative Companies
- 31.1. Bayer AG
- 31.2. Novartis AG
- 31.3. Sanofi S.A.
- 31.4. Bristol Myers Squibb
- 31.5. AstraZeneca plc
- 31.6. Abbott Laboratories
- 31.7. GlaxoSmithKline plc
- 31.8. Takeda Pharmaceutical Company
- 31.9. Eli Lilly and Company
- 31.10. C.H. Boehringer Sohn AG & Co. KG
- 31.11. Teva Pharmaceutical Industries Ltd.
- 31.12. Mylan N.V.
- 31.13. Astellas Pharma Inc.
- 31.14. Vertex Pharmaceuticals Inc.
- 31.15. Sun Pharmaceutical Industries Ltd.
32. Global Nontuberculous Mycobacterial Infection Market Competitive Benchmarking And Dashboard
33. Key Mergers And Acquisitions In The Nontuberculous Mycobacterial Infection Market
34. Recent Developments In The Nontuberculous Mycobacterial Infection Market
35. Nontuberculous Mycobacterial Infection Market High Potential Countries, Segments and Strategies
- 35.1 Nontuberculous Mycobacterial Infection Market In 2029 - Countries Offering Most New Opportunities
- 35.2 Nontuberculous Mycobacterial Infection Market In 2029 - Segments Offering Most New Opportunities
- 35.3 Nontuberculous Mycobacterial Infection Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies
36. Appendix
- 36.1. Abbreviations
- 36.2. Currencies
- 36.3. Historic And Forecast Inflation Rates
- 36.4. Research Inquiries
- 36.5. The Business Research Company
- 36.6. Copyright And Disclaimer
